Evidence map›Paper›PMID 37651185›Full record

ArticleJCI insight2023

Altered plasma metabolite levels can be detected years before a glioma diagnosis.

Sebastian Löding, Ulrika Andersson, Rudolf Kaaks, Matthias B Schulze, Valeria Pala, Ilona Urbarova, Pilar Amiano, Sandra M Colorado-Yohar, Marcela Guevara, Alicia K Heath and 6 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. N-Lactoyl Amino Acids: Emerging Biomarkers in Metabolism and Disease.Diabetes/metabolism research and reviews · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 13 institutions in 10 countries.

Sebastian LödingDepartment of Chemistry.
Ulrika AnderssonBiobank Reserach Unit, and.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Valeria PalaEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Ilona UrbarovaDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Pilar AmianoCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Sandra M Colorado-YoharCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Marcela GuevaraCIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
Alicia K HeathDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Anastasia Chrysovalantou ChatziioannouNutrition and Metabolism Branch, International Agency for Research on Cancer (IARC), Lyon, France.
Mattias JohanssonGenomic Epidemiology Branch, IARC, Lyon, France.
Lars NybergDepartment of Radiation Sciences, Diagnositc Radiology, and.
Henrik AnttiDepartment of Chemistry.
Benny BjörkblomDepartment of Chemistry.
Beatrice MelinDepartment of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.
Umeå University · SEBasque Government · ESBiothera (United States) · USCentre international de recherche sur le cancer · FRFondazione IRCCS Istituto Nazionale dei Tumori · ITGerman Cancer Research Center · DEImperial College London · GBInstitut de Génomique Fonctionnelle de Lyon · FRInstitute for Diagnosis and Animal Health · ROUiT The Arctic University of Norway · NOUniversidad de Antioquia · COUniversidad Publica de Navarra · ESUniversity of Potsdam · DE

Funding

Cancer Research UK 14136Medical Research Council MR/M012190/1World Health Organization 001
6 · The paper itself

Abstract

Genetic and metabolic changes in tissue and blood are reported to occur several years before glioma diagnosis. Since gliomas are currently detected late, a liquid biopsy for early detection could affect the quality of life and prognosis of patients. Here, we present a nested case-control study of 550 prediagnostic glioma cases and 550 healthy controls from the Northern Sweden Health and Disease study (NSHDS) and the European Prospective Investigation into Cancer and Nutrition (EPIC) study. We identified 93 significantly altered metabolites related to glioma development up to 8 years before diagnosis. Out of these metabolites, a panel of 20 selected metabolites showed strong disease correlation and a consistent progression pattern toward diagnosis in both the NSHDS and EPIC cohorts, and they separated future cases from controls independently of biological sex. The blood metabolite panel also successfully separated both lower-grade glioma and glioblastoma cases from controls, up to 8 years before diagnosis in patients within the NSHDS cohort and up to 2 years before diagnosis in EPIC. Pathway enrichment analysis detected metabolites related to the TCA cycle, Warburg effect, gluconeogenesis, and cysteine, pyruvate, and tyrosine metabolism as the most affected.

Indexed as

GlioblastomaGliomaCase-Control StudiesHumansProspective StudiesQuality of LifeBrain cancerMetabolismOncology

Identifiers

PMID37651185
PMCPMC10619434
OpenAlexW4386325094

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.